Advertisement

Real-time drug testing of paediatric diffuse midline glioma to support clinical decision making: The Zurich DIPG/DMG centre experience

Published:November 28, 2022DOI:https://doi.org/10.1016/j.ejca.2022.10.014

      Highlights

      • Robot-assisted brainstem biopsy for pontine diffuse midline gliomas (DMG) is feasible and safe.
      • Real-time drug testing on patient-derived DMG cells define individualised treatments.
      • Targeted agents as paxalisib can be successfully integrated into the care of DMG.

      Abstract

      Background

      Children diagnosed with diffuse midline gliomas (DMG) have an extremely poor overall survival: 9–12 months from diagnosis with currently no curative treatment options. Given DMG molecular heterogeneity, surgical biopsies are needed for molecular profiling and as part of enrolment into molecular-based and precision medicine type clinical interventions. In this study, we describe the results of real time profiling and drug testing at the diffuse intrinsic pontine glioma/DMG Research Centre at University Children's Hospital Zurich.

      Method

      Biopsies were taken using a frame based stereotactic robot system (NeuroMate®, Renishaw) at University Children's Hospital Zurich. Tissue samples were evaluated to confirm diagnosis by H3K27M and H3K27 trimethylation loss. Genomic analyses were done using a variety of platforms (INFORM, Oncomine, UCSF500 gene panel).
      Cell lines were developed by mechanical tissue dissociation and verified by either sequencing or immunofluorescence staining confirming H3K27M mutation and used afterwards for drug testing.

      Results

      Twenty-five robot-assisted primary biopsies were successfully performed. Median hospital stay was 2 days (range 1–4 days). Nine low-passage patient-derived cells were developed, whereas 8 cell lines were used to inform response to clinically relevant drugs. Genome and RNA expression were used to further guide treatment strategies with targeted agents such as dual PI3K/mTOR inhibitor paxalisib.

      Conclusion

      We established a systematic workflow for safe, robot-assisted brainstem biopsies and in-house tissue processing, followed by real-time drug testing. This provides valuable insights into tumour prognostic and individual treatment strategies targeting relevant vulnerabilities in these tumours in a clinically meaningful time frame.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Ostrom Q.T.
        • Patil N.
        • Cioffi G.
        • Waite K.
        • Kruchko C.
        • Barnholtz-Sloan J.S.
        • et al.
        CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2013-2017.
        Neuro Oncol. 2020; 22: iv1-iv96
        • Vanan M.I.
        • Eisenstat D.D.
        DIPG in children – what can we learn from the past?.
        Front Oncol. 2015; 5: 237
        • Mackay A.
        • Burford A.
        • Carvalho D.
        • Izquierdo E.
        • Fazal-Salom J.
        • Taylor K.R.
        • et al.
        Integrated molecular meta-analysis of 1,000 pediatric high-grade and diffuse intrinsic pontine glioma.
        Cancer Cell. 2017; 32: 520-537 e5
        • Pfaff E.
        • El Damaty E.
        • Balasubramanian G.P.
        • Blattner-Johnson M.
        • Worst B.C.
        • Stark S.
        • et al.
        Brainstem biopsy in pediatric diffuse intrinsic pontine glioma in the era of precision medicine: the INFORM study experience.
        Eur J Cancer. 2019; 114: 27-35
        • Gupta N.
        • Goumnerova L.
        • Manley P.
        • Chi S.N.
        • Neuberg D.
        • Puligandla M.
        • et al.
        Prospective feasibility and safety assessment of surgical biopsy for patients with newly diagnosed diffuse intrinsic pontine glioma.
        Neuro Oncol. 2018; 20: 1547-1555
        • Puget S.
        • Beccaria K.
        • Blauwblomme T.
        • Roujeau T.
        • James S.
        • Grill J.
        • et al.
        Biopsy in a series of 130 pediatric diffuse intrinsic Pontine gliomas.
        Childs Nerv Syst. 2015; 31: 1773-1780
        • Gupta M.
        • Chan T.M.
        • Santiago-Dieppa D.R.
        • Yekula A.
        • Sanchez C.E.
        • Elster J.D.
        • et al.
        Robot-assisted stereotactic biopsy of pediatric brainstem and thalamic lesions.
        J Neurosurg Pediatr. 2020; : 1-8
        • Mueller S.
        • Jain P.
        • Liang W.S.
        • Kilburn L.
        • Kline C.
        • Gupta N.
        • et al.
        A pilot precision medicine trial for children with diffuse intrinsic pontine glioma-PNOC003: a report from the Pacific Pediatric Neuro-Oncology Consortium.
        Int J Cancer. 2019; 145: 1889-1901
        • Worst B.C.
        • van Tilburg C.M.
        • Balasubramanian G.P.
        • Fiesel P.
        • Witt R.
        • Freitag A.
        • et al.
        Next-generation personalised medicine for high-risk paediatric cancer patients – the INFORM pilot study.
        Eur J Cancer. 2016; 65: 91-101
        • Kim S.W.
        • Park B.J.
        • Kim H.
        • Na K.
        • et al.
        Diagnostic utility of oncomine comprehensive assay v3 in differentiating between isocitrate dehydrogenase (IDH)-mutated grade II-III astrocytoma and oligodendroglioma.
        In Vivo. 2021; 35: 921-927
        • Kline C.N.
        • Joseph N.M.
        • Grenert J.P.
        • van Ziffle J.
        • Talevich E.
        • Onodera C.
        • et al.
        Targeted next-generation sequencing of pediatric neuro-oncology patients improves diagnosis, identifies pathogenic germline mutations, and directs targeted therapy.
        Neuro Oncol. 2017; 19: 699-709
        • Duchatel R.J.
        • Mannan A.
        • Woldu A.S.
        • Hawtrey T.
        • Hindley P.A.
        • Douglas M.D.
        • et al.
        Preclinical and clinical evaluation of German-sourced ONC201 for the treatment of H3K27M-mutant diffuse intrinsic pontine glioma.
        Neurooncol Adv. 2021; 3: vdab169
        • Przystal J.M.
        • Cosentino C.C.
        • Yadavilli S.
        • Zhang J.
        • Laternser S.
        • Bonner E.R.
        • et al.
        Imipridones affect tumor bioenergetics and promote cell lineage differentiation in diffuse midline gliomas.
        Neuro Oncol. 2022; 24: 1438-1451
        • Tinkle C.
        • Huang J.
        • Campagne O.
        • Pan H.
        • Onar-Thomas A.
        • Chiang J.
        • et al.
        CTNI-27. FIRST-IN-PEDIATRICS PHASE I STUDY OF GDC-0084 (PAXALISIB), A CNS-PENETRANT PI3K/mTOR INHIBITOR, IN NEWLY DIAGNOSED DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) OR OTHER DIFFUSE MIDLINE GLIOMA (DMG).
        Neurooncology. 2020; 22 (ii48–ii48)
        • Hamisch C.
        • Kickingereder P.
        • Fischer M.
        • Simon T.
        • Ruge M.I.
        • et al.
        Update on the diagnostic value and safety of stereotactic biopsy for pediatric brainstem tumors: a systematic review and meta-analysis of 735 cases.
        J Neurosurg Pediatr. 2017; 20: 261-268
        • Maury E.
        • Hashizume R.
        Epigenetic modification in chromatin machinery and its deregulation in pediatric brain tumors: insight into epigenetic therapies.
        Epigenetics. 2017; 12: 353-369
        • Bender S.
        • Tang Y.
        • Lindroth M.A.
        • Hovestadt V.
        • Jones D.T.
        • Kool M.
        • et al.
        Reduced H3K27me3 and DNA hypomethylation are major drivers of gene expression in K27M mutant pediatric high-grade gliomas.
        Cancer Cell. 2013; 24: 660-672
        • Castel D.
        • Kergrohen T.
        • Tauziède-Espariat A.
        • Mackay A.
        • Ghermaoui S.
        • Lechapt E.
        • et al.
        Histone H3 wild-type DIPG/DMG overexpressing EZHIP extend the spectrum diffuse midline gliomas with PRC2 inhibition beyond H3-K27M mutation.
        Acta Neuropathol. 2020; 139: 1109-1113
        • Louis D.N.
        • Perry A.
        • Wesseling P.
        • Brat D.J.
        • Cree I.A.
        • Figarella-Branger D.
        • et al.
        The 2021 WHO classification of tumors of the central nervous system: a summary.
        Neuro Oncol. 2021; 23: 1231-1251
        • Mueller T.
        • Postlmayr A.
        • Metzger S.
        • Gerber N.
        • Kline C.
        • Grotzer M.
        • et al.
        Advances in targeted therapies for pediatric brain tumors.
        Curr Treat Options Neurol. 2020; 22: 1-24
        • Hoeman C.M.
        • Cordero F.
        • Hu G.
        • Misuraca K.
        • Romero M.M.
        • Cardona H.J.
        • et al.
        ACVR1 R206H cooperates with H3.1K27M in promoting diffuse intrinsic pontine glioma pathogenesis.
        Nat Commun. 2019; 10: 1023
        • Chen S.
        • Wu J.
        • Liang Y.
        • Tang Y.
        • Song H.
        • Wu L.
        • et al.
        Arsenic trioxide rescues structural p53 mutations through a cryptic allosteric site.
        Cancer Cell. 2021; 39: 225-239 e8
        • Xu C.
        • Liu X.
        • Geng Y.
        • Bai Q.
        • Pan C.
        • Sun Y.
        • et al.
        Patient-derived DIPG cells preserve stem-like characteristics and generate orthotopic tumors.
        Oncotarget. 2017; 8: 76644-76655
        • Tsoli M.
        • Shen H.
        • Mayoh C.
        • Franshaw L.
        • Ehteda A.
        • Upton D.
        • et al.
        International experience in the development of patient-derived xenograft models of diffuse intrinsic pontine glioma.
        J Neuro Oncol. 2019; 141: 253-263
        • Wen P.Y.
        • de Groot J.
        • Battiste J.D.
        • Goldlust S.A.
        • Garner J.
        • Simpson J.
        • et al.
        Abstract CT205: phase 2 study to evaluate the safety, pharmacokinetics, and clinical activity of the PI3K/mTOR inhibitor paxalisib (GDC-0084) in glioblastoma (GBM) with unmethylated O6-methylguanine-methyltransferase (MGMT) promotor status.
        Cancer Res. 2020; 80 (CT205–CT205)
        • Fiani B.
        • Covarrubias C.
        • Onyedimma C.
        • Jarrah R.
        • et al.
        Neurocytological advances in the treatment of glioblastoma multiforme.
        Cureus. 2021; 13e16301